Disialoganglioside-specific human natural killer cells are effective against drug-resistant neuroblastoma.

The disialoganglioside GD2 is a well-established target antigen for passive immunotherapy in neuroblastoma (NB). Despite the recent success of passive immunotherapy with the anti-GD2 antibody ch14.18 and cytokines, treatment of high-risk NB remains challenging. We expanded the approach of GD2-specific, antibody-based immunotherapy to an application of a GD2-specific natural killer (NK) cell line, NK-92-scFv(ch14.18)-zeta. NK-92-scFv(ch14.18)-zeta is genetically engineered to express a GD2-specific chimeric antigen receptor generated from ch14.18. Here, we show that chimeric receptor expression enables NK-92-scFv(ch14.18)-zeta to effectively lyse GD2(+) NB cells also including partially or multidrug-resistant lines. Our data suggest that recognition of GD2 by the chimeric receptor is the primary mechanism involved in NK-92-scFv(ch14.18)-zeta-mediated lysis and is independent of activating NK cell receptor/ligand interactions. Furthermore, we demonstrate that NK-92-scFv(ch14.18)-zeta is able to mediate a significant anti-tumor response in vivo in a drug-resistant GD2(+) NB xenograft mouse model. NK-92-scFv(ch14.18)-zeta is an NB-specific NK cell line that has potential for future clinical development due to its high stability and activity toward GD2(+) NB cell lines.
AuthorsDiana Seidel, Anastasia Shibina, Nikolai Siebert, Winfried S Wels, C Patrick Reynolds, Nicole Huebener, Holger N Lode
JournalCancer immunology, immunotherapy : CII (Cancer Immunol Immunother) Vol. 64 Issue 5 Pg. 621-34 (May 2015) ISSN: 1432-0851 [Electronic] Germany
PMID25711293 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Chemical References
  • Antibodies, Anti-Idiotypic
  • Gangliosides
  • Receptors, Antigen
  • Single-Chain Antibodies
  • sialogangliosides
  • ganglioside, GD2
  • Animals
  • Antibodies, Anti-Idiotypic (immunology)
  • Cell Line
  • Cytotoxicity, Immunologic (immunology)
  • Drug Resistance, Neoplasm
  • Female
  • Gangliosides (genetics, immunology)
  • Genetic Engineering
  • Humans
  • Immunotherapy, Adoptive (methods)
  • Killer Cells, Natural (immunology)
  • Mice
  • Mice, Inbred NOD
  • Neoplasm Transplantation
  • Neuroblastoma (immunology, therapy)
  • Receptors, Antigen (biosynthesis, immunology)
  • Single-Chain Antibodies (immunology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: